Strategic Agreement Between Sapphiros and Roche: Revolutionizing Diagnostic Testing for Future Health Crises

A recent agreement has positioned Sapphiros and Roche to lead the charge in pandemic preparedness and rapid health crisis responses. This partnership, announced on November 19, 2025, is set to revolutionize diagnostic testing by ensuring swift global access to critical tests for future pandemics and health emergencies.

Securing Access to Rapid Testing

At the heart of this collaboration is the ability of Sapphiros to supply Roche with at least 1 billion tests annually. This impressive capacity stems from Sapphiros’ proprietary manufacturing process, designed to operate at extreme volumes in the UK. With a total manufacturing capability of up to 5 billion diagnostics each year, Sapphiros is well-equipped to meet the growing demand for healthcare solutions in urgent situations.

Innovative Manufacturing Process

Sapphiros’ reel-to-reel automated manufacturing technology plays a crucial role in this endeavor. The process is not only efficient but also scales effectively to accommodate vast quantities of testing supplies. The strategic significance of this facility cannot be overstated, particularly as we look toward future public health crises that require a nimble and robust response.

Access to Advanced Testing Technologies

Under this agreement, Roche will gain more than just manufacturing capacity; it will also have access to Sapphiros’ novel molecular multiplex technology. This groundbreaking platform is particularly notable for its simplicity and ease of use. Designed for point-of-care and home testing, it enables healthcare providers and patients alike to conduct tests without the need for complicated instruments. This instrument-free approach aims to democratize access to diagnostics, potentially revolutionizing the way tests are administered in both clinical and home settings.

Commitment to Public Health

Mark Gladwell, CEO of Sapphiros, emphasized the company’s long-standing commitment to innovation in diagnostics and equitable health outcomes. He stated, "Our unique reel-to-reel automated manufacturing capability together with our collective priority of long-term pandemic preparedness places both companies at the forefront playing a critical role in responding to future health emergencies." This shared vision demonstrates their dedication not only to advancing technology but also to ensuring that all communities benefit from improved health outcomes.

Roche’s Diagnostic Expertise

Roche’s involvement adds a layer of credibility and expertise that cannot be overlooked. Ian Parfrement, Head of Near Patient Care for Roche Diagnostics, noted the vital role that diagnostics play in managing public health. He highlighted the importance of early and precise identification of infections, saying, "This collaboration is further evidence of the role Roche can play, as a partner to global public health bodies, in helping to reduce the spread of infectious disease in the event of a future pandemic."

Aiming for Accessibility and Simplicity

Both Sapphiros and Roche share a mutual goal: to make diagnostics simple, scalable, and accessible to all. This partnership underscores their commitment to supporting governments, health systems, and communities in their efforts to combat future pandemics through prompt and reliable testing solutions. The collaboration stands as a testament to what can be achieved when innovative technology meets a shared commitment to global health.

About Sapphiros

For those unfamiliar with Sapphiros, it is a privately held consumer diagnostics company, supported by KKR and Neoenta. The company’s diverse portfolio includes advanced sample collection methods, next-generation diagnostic technologies, and manufacturing capabilities that ensure important diagnostic results reach consumers and communities efficiently.

For further insights into this pivotal partnership and Sapphiros’ initiatives, you can visit their website at www.sapphiros.com.

This agreement positions both Sapphiros and Roche at the forefront of a new era in diagnostics, paving the way for future innovations that could profoundly impact global health strategies.